Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 ( 
Introduction
The application of radionuclides as a targeted therapy in oncology has returned to the starting lineup with renewed interest and scientific enthusiasm. As an overall strategy, the utilization of targeting moieties increases specificity in radionuclide delivery to sites of locally advanced or metastatic disease, minimizing unwanted toxicities from non-specific distribution of therapeutic agents. Currently, there are two FDA-approved targeted radionuclide therapies for the treatment of non-Hodgkin lymphoma, 131 I-tositumomab (Bexxar®) and 90 Y-ibritumomab tiuxetan (Zevalin®) [1] . Both of these utilize radionuclides that decay through the emission of β-particles.
The investigation and development of α-emitter radionuclide conjugates for therapy is rapidly expanding the targeted therapy concept based on strong scientific evidence. A major milestone has been reached recently with the FDA approval of the first α-emitter, Radium-223 ( 223 Ra) dichloride (Xofigo®), for the treatment of prostate cancer with metastatic bone disease (http://www.fda.gov/Drugs/InformationOnDrugs/ ApprovedDrugs/ucm352393.htm).
The interest in α-emitters stems from the highly cytotoxic effect of their high-linear energy transfer (LET) and short path length of 50-100 μm. This is different from β-emitters that have two drawbacks: a long electron path length, causing unwanted
Key Points
(1) Targeted alpha therapy results in cytotoxic effects (2) Toxicities can be minimized by improving target (3) There is significant increase in clinical trials using and presents novel opportunities for cancer treatment moieties and chelators novel targeted alpha therapies radiation exposure to normal tissue, and inefficiency in cell killing due to the low-LET of an electron [2] . Figure 1 illustrates the difference between α-and β-particle path-lengths and ionization density. Data have shown that single decay events from α-emitters can effectively destroy a single cancer cell [3, 4] . The emitted α-particle causes dense ionizations within a cell nucleus, resulting in double-strand DNA breaks and cell death, establishing the high relative biological effectiveness (RBE) of α-particle emissions used to kill diseased cells as a therapeutic effect [5] . This cytotoxic effect can also overcome acquired resistance to β-emitters, conventional external beam radiation, or cytotoxic agents. Theoretically, the exposure of the α-particle emissions to non-target tissues creates unwanted toxicity, but the risk is minimized over β-emitters. Actinium-225 ( 225 Ac) and Bismuth-213 ( At) are four of the multiple α-emitting radionuclides, which have been investigated in both pre-clinical and clinical studies. The major hindrance to the advancement of the therapeutic application of α-emitters is the availability of the radionuclides. In 2008 and again in 2015, the Nuclear Science Advisory Committee (NSACI) identified 225 Ac and the research and development of α-emitters as high priorities, [6] and in 2011 the International Atomic Energy Association (IAEA) addressed accelerator production of 225 Ac as a top research priority [7] . Furthermore, pharmaceutical companies have developed innovative methods for α-emitter production, with unlimited capacity to produce high-purity 212 Pb as an example, extracted from a vast supply of natural thorium salt generated from nuclear reactors [8] .
This review offers the compilation of the current status and future perspectives on targeted alpha therapy (TAT) when these α-emitters are combined with peptides, monoclonal antibodies, or small molecules. In this review, we will cover the production methods, historical and novel chelates, pre-clinical trials, and clinical studies. Bi for therapeutic application to large patient populations [11, 12] . The current method of producing 225 Ac and its daughter, 213 Bi, stem from efforts to produce fissile 233 Bi provide sufficient quantities for pre-clinical and small clinical trials, they will be unable to meet the demands of global therapeutic application in medicine [11] . Therefore, alternative production methods using large-scale accelerators are currently being investigated [15, 16] . Table 1 provides information on the current production of the clinically relevant α-emitters 
Production and Supply

Bismuth-213 ( 213
Bi)
With the availability of 225 Ac, the assembly and use of the 225 Ac/ 213 Bi generator becomes possible. This generator has clinically favorable qualities, including a relatively long parent halflife ( 225 Ac t½ = 10 days) and a relatively short-lived daughter radionuclide ( 213 Bi t½ = 45.8 min). This allows for shipment of the generator across greater distances to various institutions. The transient equilibrium of the parent-daughter radionuclides also allows generator elution every 2-3 h [11] . The availability of these generators could provide weeks to months of in-house generation of 213 Bi for radiolabeling therapeutic conjugates [25] . The major limitation of this method is the availability of parent 225 Ac, as previously discussed. However, 225 Ac produced via high-energy accelerators would be completely suitable for generator production, even with co-production of 227 Ac. The 213 Bi generator is a very realistic approach to At [20, [26] [27] [28] [29] [30] [31] [32] .
Radionuclidic Properties and Chemistry
Radionuclidic properties of clinically relevant α-emitters are summarized in Fig. 2 . These physical properties make 225 Ac, 213 Bi,
212
Pb, and 211 At favorable therapeutic radionuclides due to their rapid decay, α-particle emissions, and the relative lack of dosimetrically troubling emissions [33] .
Biodistribution Chelates and Metabolism of Radionuclides
The evaluation of the biodistribution of α-emitters plays an important role in understanding the fate of these radioisotopes. In the 1960s, bismuth and other elements within this chemical family were evaluated in vivo and it was determined that bismuth uptake occurs mostly in the kidney [34, 35] . In the following years, 227 Ac biodistribution was studied in male rats, concluding that 227 Ac was a liver seeker [36] .
The results of this study showed that organ accumulation decreased with increasing 225 Ac-complex stability. The liver accumulation increased with decreasing complex stability, with liver accumulation of acetate > EDTA > PEPA ≈ CHX-DTPA. The efforts to decrease liver accumulation and toxicity of α-emitters led to further development of chelates capable of forming very stable complexes. Ac has been conjugated as a bone seeker [37] , an antiviral or antibacterial agent [38] , as well as in many liposomal and carbon nanotube constructs to improve delivery and retention of the isotope and its progeny [39] [40] [41] [42] [43] [44] . The immunoconjugate 225 Ac linked-trastuzumab was tested on ductal carcinoma in situ (DCIS) of the breast [45] . The intraductal route was used in NSG mice to compare the toxicity and efficacy with the intravenous route. Dose ranged from 1.11 to 4.44 kBq per mouse for the intraductal injection and was 4.44 kBq per mouse for the intravenous one. Results showed better response for the intraductal administration (p < 0.0003). The local administration led to no kidney toxicity and no weight loss. An anti-vascular approach in glioblastoma in Ntva-mice was experienced in 2016 [46] . 225 Ac was coupled to an anti-VE-cadherin antibody (E4G10) to target vascular endothelial cells. 225 Ac-E4G10 induced changes in the tumor microenvironment at a dose of 7.4 kBq. Those changes involved vascular remodeling, edema relief, and decrease of the T-cell population.
5.2 213 
Bi-Conjugates
After the initial reported use of 213 Bi in TAT, there has been a large body of in vitro and in vivo work [47] . In 1992, Huneke et al. [48] reported successful α-particle RIT for mouse leukemia. In 1999, Behr et al. [4] demonstrated the higher RBE with high-LET α-particles compared to low-LET β-particles [49] . In this same year, 213 Bi was conjugated to the antibody HuM-195 and was evaluated for pharmacokinetics and toxicity. In vivo experiments examined an antibody to target prostate cancer [50] . RIT with α-particle emitting radionuclides were shown to break chemoresistance and radioresistance in leukemia [51] . A tremendous amount of successful work has been accomplished with 213 Bi-TAT utilizing different targeting moieties such as antibodies, antibody fragments, peptides, and liposomal antibodies by systemic and locoregional administration. 213 Bi-DOTATATE was used in combination with L-lysine in order to reduce the renal uptake in athymic mice [52] . MTD was increased from <13.0 ± 1.6 MBq in the control to 21.7 ± 1.9 MBq with the L-lysine. No effect on the tumor uptake, improved overall survival, and decrease of the tumor burden were reported. Long-term toxicity was experienced on NMRI-nu mice for 213 Bi-labeled BSA [53] . Mice were monitored for 385 days. Results revealed a consistency with the liver damage previously observed in human clinical trials. Increased plasma creatinine and BUN confirmed the long term risk of nephrotoxicity.
Other studies have set the stage for the advancement of successful clinical application. 213 Bi has favorable qualities such as a short half-life, and good incorporation kinetics that make it a strong candidate for TAT. Although 213 Bi is not as cytotoxic as 225 Ac, it is much easier to apply to future clinical developments due to its chemical properties and lack of daughter radionuclides. The applications of 213 Bi-TAT, like RIT and PRRT, have become of significant importance in the clinical setting. Pb has been performed, whereby 203 Pb allows gamma imaging and dosimetry. In 2012, we have reported the therapeutic effect of 212 Pbtrastuzumab in an orthotopic model of human prostate cancer cells (PC-3MM2) [54] . In this model with low level of expression of HER2, the therapy administered i.v. has shown a tumor volume reduction by 60-80% on the primary lesion and distant metastatic lymph nodes with a prolonged survival. No significant toxicity was reported. More recently, 212 Pb was conjugated to mAb376.96, a mouse mAb that binds the B7-H3 epitope found on ovarian cancer cells. Results showed increased survival time (2-3 times longer) in the tumorbearing mice [55] .
211
At-Conjugates
211
At has been conjugated to multiple targeted agents, including small molecules, peptides, and antibodies. Some of the earliest work with 211 At was performed at Duke University, where they developed multiple small molecules [56] . Radiolabeled peptides that target prostate specific membrane antigen (PSMA) have been developed as positron emission tomography (PET) imaging agents for the detection of recurrent prostate cancer. Recently, a radiohalogented PSMAtargeted peptide (2S)-2-(3-(1-carboxy-5-(4- 2 11 Atastatobenzamido)pentyl)ureido)-pentanedioic acid was reported and showed in vivo efficacy in pre-clinical models of prostate cancer [57] . Toxicities were limited to late nephrotoxicity due to high accumulation of PSMA-targeted agents in the proximal tubules of the kidneys. Antibodies have also been explored as 211 At-targeted agents. In summary, multiple preclinical studies have been performed using 211 At-targeted agents for α-particle therapy in cancer providing a strong rationale for future clinical translation [58] (Table 2) .
Pharmacologic Interventions and Radiobiology
The radiobiology of α-particles has been studied in great depth. In the 1960s, Barendsen et al. [5] first conducted a series of experiments to examine the repair mechanisms of mammalian cells in tissue culture after radiation damage by fractionation. In these experiments the tissue cultures were exposed to different types of radiation at varying energies for a given amount of time, followed by a radiation-free period, in order to observe the repair capabilities. This study observed that α-particles had a high-LET that resulted in densely ionizing paths that were completely destructive to the individual cells with no chance of repair following radiation exposure [6] .
In 2005, Jaggi et al. [74] examined the radiobiology effects of TAT in vivo. 225 Ac was injected into mice to study the morphological and functional changes of the kidneys [75] . Efforts are necessary to control the renal toxicity observed with 225 Ac and 213 Bi. Pharmacologic treatments were tested in mice and non-human primates to evaluate the tumor burden as well as to decrease toxicity [76] . Oral chelation therapy with DMPS and DMSA significantly reduced renal uptake. This reduction was further potentiated by the administration of diuretics such as furosemide or chlorothiazide [75] . A similar experiment was conducted using spironolactone and showed reduction in renal uptake, averting unwanted toxicities [76] . The use of administration of lysine prior to TAT has been reported to have a threefold reduction in the kidney uptake of 213 Bi and its conjugates [77, 78] . Other attempts to increase tumor uptake and decrease off-target uptake of α-particle emitting therapeutic conjugates have been reported. Inhibiting the FcRn led to an increase tumor-to-background ratio and decreased normal tissue toxicity [79] . Improvement in clinical effectiveness has been reported when a radiohaptan that binds to a site-specific antibody is used in advance of therapy with β-emitting isotopes [80] . This approach takes advantage of the fast blood and whole-body clearance of the haptan and the site-specific targeting of the antibody.
More recently, studies have focused on the utilization of targeting molecules to enhance the therapeutic effect of the α-emitter. There is an obvious advantage of generating the α-particle emission on the surface of the cell given the relatively short range of the particle. Prise [81] discusses the bystander and abscopal effect of chemotherapy, external beam and radionuclide therapy and the potential for bystander and distant effects. One study compares radionuclide specific effects as demonstrated by the difference in saturation of the bystander effect in low LET isotope ( 131 I) versus high LET ( 123 I or 211 At) [82] . The 131 I-radiolabeled molecule shows no saturation of effect on unirradiated cells exposed to media from exposed cells, whereas both high LET molecules do demonstrate saturation and then loss of effect at higher doses. No explanation is provided for this difference. As these studies were done in vitro, it is possible that in vivo studies will not demonstrate the difference in effect.
A more recent publication demonstrated an effect that might explain the abscopal experience [83] . They demonstrated that alpha treatment of prostate cancer cells generated an adaptive antitumoral immune response, as has been previously reported for other forms of radiation. The combination of bystander effects and the abscopal (likely immune) response in vivo demonstrates the efficacy of α-emitter radiotherapy.
The major limitation to TAT is unwanted off-target uptake that results in toxicities. Following systemic administration, 225 Ac may be released from the chelate and deposited within the liver. Following radioactive decay, the progeny may be released from the chelate, resulting in radionuclidic deposition in different organs. As an example, the small intestine will receive a radiation dose, but the toxicities will be short term due to the rapidly dividing nature of the tissue. If 225 Ac and all of its progeny cannot remain bound to the targeting vector long enough to reach the site of action and remain at the site of action, toxicities will ensue. As mentioned above, this concept does not apply to 213 Bi due to its short half-life (45.6 min). The tissue distribution of unbound radionuclides can be found in Table 3 .
Dosimetry
Internal radiation dosimetry is the calculation of energy deposited in a given tissue by a radioactive decay event [103] . The Medical Internal Radiation Dosimetry (MIRD), or the fraction method, provides the most accurate dosimetric calculations and is the standard for calculating internal radiation dosimetry [104] . The dosimetry of α-emitters is often complicated by multiple progeny with different pharmacokinetic profiles and chemical qualities. Each decay event from the parent nuclide to the last stable daughter is considered in the calculation. The decay site of the parent nuclide influences where the progeny will decay and has been modeled by a probability matrix. The fate of the progeny nuclides have been evaluated using dose conversion factors that can help understand whether the daughter nuclide will decay at the same site as the parent or if it will redistribute to another tissue [105] . A model to help predict the dosimetry for α-emitters like 225 Ac has been described and takes into account the parent site of decay, the daughter half-lives, the biodistribution of the daughters, the transient blood time, and the tumor uptake [105] . The clinical implications and guidance have been reported in the recent MIRD pamphlet no. 22 [106] . Alpha-emitters are used within two strategies, the first one, TAT, is a targeted strategy involving antibodies, peptides, or other moieties, and the second one is non-specific based on chemical mimetics that preferentially bind specific tissues and increase local drug concentration. As developed in this section, 225 Ac,
211
At, 213 Bi, and 212 Pb have been linked to some antibodies to allow a specific distribution to their target. By contrast, 223 Ra is used as a chemical compound, 223 Ra dichloride. It is maintained by ionic bond, which mimics calcium and thereby forms complexes with hydroxyapatite at areas of increased bone turnover, such as bone metastases [107] .
Therapies involving an α-emitter have been investigated in a broad spectrum of diseases, including leukemia, lymphoma, melanoma, brain tumors, neuroendocrine tumors, ovarian carcinomas, peritoneal carcinomatosis, prostate, and breast cancers. Currently, more than fifteen clinical trials, worldwide, have investigated the potential of α-emitting radiopharmaceuticals, leading to the FDA approval of one of them, 223 Ra (Table 4 ).
225 Ac
In 2011, the results of the first-in-human phase 1 clinical trial involving 225 Ac-DOTA-SCN were presented at the ASCO Annual Meeting [84] . This study was a dose escalation to determine the safety, the pharmacological and the biological activity of 225 Ac coupled with lintuzumab in acute myeloid leukemia (AML). Lintuzumab is a humanized anti-CD33 antibody, which targets myeloid leukemia cells and has a known activity against AML as a single agent. No acute toxicities were observed and transient grade 2/3 liver function abnormalities were the only extramedullar toxicities. Dose-limiting toxicity (myelosuppression lasting >35 days; death due to sepsis) occurred in one patient who received 30.11 MBq/kg and in the two patients at the 0.15 MBq/kg dose level [84] . Bone marrow blasts reduction >33% occurred in 10 of 15 evaluable patients (67%) at week 4. This study established that the 225 Ac is tolerable at 0.11 MBq/kg and demonstrated promising preliminary antileukemic activity. A phase I trial was built on those results to determine the maximum tolerated dose (MTD) and efficacy of fractioned dose 225 Ac-lintuzumab in combination with low-dose cytarabine (LDAC) [85] . Doselimiting toxicity (DLT), grade 4 thrombocytopenia, and pancytopenia >6 weeks after therapy, occurred at 0.037 MBq/kg/ fraction in one patient. Grade 3/4 toxicities including febrile neutropenia, thrombocytopenia, neutropenia, and pneumonia appeared within the trial. Progression-free survival (PFS) ranged from 1.3 to 16.9 months, with a median of 2.4 months. After one cycle, six of eight evaluable patients (75%) had bone marrow blast reductions (mean reduction, 68%; range, 34-100%) and blast reduction of ≥50% occurred in five patients (63%). No complete remissions were observed to date in this ongoing study. More recently, Kratochwil et al. [86] combined 225 Ac with the prostate-specific membrane antigen (PSMA): 225 Ac-PSMA-617. With an activity of 100-kBq per kg of body weight administered bimonthly, two patients with diffuse red marrow infiltration of mCRPC and peritoneal carcinomatosis with liver metastases, respectively, presented a complete response. Clinically, only xerostomia was reported among the two patients (moderate but enduring for one patient, and requiring spray substitution of saliva for the second). From a biochemical standpoint, both of their PSA level dropped concurring with a treatment response.
211 At
In 2008, Zalutsky et al. [87] published the results of a first-inhuman study involving 211 At labeled to a chimeric antitenascin monoclonal antibody 81C6 (ch81C6). Eighteen patients with recurrent malignant primary brain tumors were given 211 At-ch81C6 administered locally into the surgical bed and then followed by chemotherapy. DLT did not occur in any patients and the MTD was not reached. The median survival time was 52, 54, and 116 weeks for anaplastic astrocytoma, glioblastoma multiforme, and oligodendroglioma, respectively.
211
At, coupled with a monoclonal antibody, MX35 F(ab') 2 , entered a phase I study. MX35 F(ab') 2 targets the sodiumdependent phosphate transport protein 2b (NaPi2b). This antigen is overexpressed in >90% of human ovarian epithelial Bi was used in combination in several trials, and both systemic and local administration strategies were explored.
Systemic Administration
HuM195 is a humanized monoclonal antibody, which targets the CD33 antigen expressed on most myeloid leukemia and leukemia progenitor cells. After being conjugated to 213 Bi, this compound interred a phase I study including 18 patients with relapsed and refractory acute myelogenous leukemia or chronic myelomonocytic leukemia. 213 Bi doses ranged from 10.36 to 37.0 MBq/kg. No significant extramedullary toxicity was seen and myelosuppression occurred in all the 17 evaluable patients. Fourteen of 18 evaluable patients showed reductions in circulating blasts and bone marrow percentage blasts decreased in 14 of 18 patients. 213 Bi-HuM195 quickly localized in bone marrow, liver, and spleen [90] . 213 Bi was also used in AML in a phase I/II trial testing the combination with lintuzumab, another humanized anti-CD33 monoclonal antibody in combination with cytarabine. MTD occurred at 37 MBq/kg, and the dose-limiting toxicity was defined by myelosuppression lasting >35 days. Treatmentrelated deaths occurred in 2 of 21 patients, they were receiving the MTD. However, significant reductions in marrow blasts were observed within all dose levels [91] .
In 2007, an interim analysis of the use of 213 Bi-cDTPA-9.2.27 mAb was published. The mAb 9.2.27 is an antibody which targets the anti-neural/glial antigen 2 (NG2). This human melanoma proteoglycan is expressed in melanoma cell lines. Twenty-two patients with stage IV melanoma, participated in a phase I dose escalation study to assess toxicity and response to the systemic administration of this alpha immunoconjugate (AIC). Fifty percent of the patients showed stable disease and 14% showed a partial response (according to RECIST criteria). No toxicity was reported over the scope of administered activities [92] . The MTD was not achieved. In 2017, Sathekge et al. [93] published the result of another targeted α-radionuclide therapy using PSMA in mCRPC. 213 Bi-PSMA-617 was given for two cycles at a total dose of 592 MBq. The patient showed complete response via imaging and his PSA level decreased more than 5 times [94] .
Local Administration
In 2005, Allen et al. [95] reported the safety and efficacy of an intralesional TAT in melanoma. This compound resulted in benign targeting vector 9.2.27 labeled with 213 Bi. Two weeks after the TAT, evidence of significant decrease in serum marker-melanoma-inhibitory-activity protein (MIA) was detected.
A pilot trial used 213 Bi combined with the chelator DOTA and Substance P, the physiological ligand of NK-1 receptors known to be overexpressed in WHO grades II-IV gliomas. No relevant acute local or systemic toxicity was reported. Patients, with relatively small tumors, experienced the most benefit from this local injection. Further evaluation of this concept, in small, symptomatic high-grade gliomas, is planned [96] .
The most recent α-therapy involving 213 Bi started in 2010. Neuroendocrine tumors were targeted using 213 Bi-DOTATOC (a somatostatin analogue) in a first-in-human trial. Moderate acute hematological toxicity was reported and kidneys were the only organs, which experienced toxicity. In addition, results showed that it was possible to overcome the resistance to the previous β-emitter therapy as enduring responses were observed in all treated patients [97] .
212 Pb
In 2013, 212 Pb was used in a first in human dose escalation clinical trial [98] . It was combined with trastuzumab and TCMC, a metal chelating agent.
212
Pb-TCMC-trastuzumab was well tolerated with grade 1 liver test function increase (not dose related) among nine patients, grade 1 leukopenia without neutropenia, and grade 1 thrombocytopenia, in two patients, and creatinine increase without proteinuria, grade 1, for four patients. Dosimetry showed that the organ equivalent dose was higher in the peritoneal fluid, osteogenic cells, and small intestine, than in the other organs. Within the 8 months, disease progression (bowel obstruction) was seen in all patients. After 1 year of follow-up, no cardiotoxicity, hepatoxicity, nephrotoxicity, or other toxicities were witnessed [98] . Ra entered a first in human phase I dose escalation study for skeletal metastases [99] . Dose-limiting hemotoxicity was not observed. Grade 3 neutropenia and leukopenia occurred in the same two patients (dosage group 3 and 5) in addition to a patient in dosage group 4. Reversible myelosuppression was seen, and followed by a complete recovery (nadir 2-4 weeks after injection). There was a correlation between dose and myelosuppression. Transient diarrhea, bone pain, including Bflare^, fatigue, nausea and vomiting were the most described adverse events in this study. The drug elimination was mainly within the intestinal and hepatobiliary tract. Pain relief was reported by 52% of the patients after 7 days. The median survival was more than 20 months for all patients. Based on these encouraging preliminary results, further studies have been conducted. 
Conclusions
In this paper we have reviewed major areas of interest regarding five radionuclides and their application to therapy. There is now a large data set of in vitro and in vivo experiments, establishing the therapeutic cytotoxic efficacy of targeted constructs containing 225 Ac, 213 Bi, 212 Pb, 211 At, and 223 Ra.
Although 225 Ac is more cytotoxic, it seems virtually impossible to maintain chelation of the daughter radionuclides after an α decay event. The challenge of controlling the fate of the daughters will have to be considered in any application of 225 Ac. The clinical effectiveness of 213 Bi demands greater exploration, as it displays good therapeutic cytotoxicity and can be chelated adequately. The targeting moieties for 213 Bi need further investigation. 213 Bi has a short half-life and needs to be attached to a targeting moiety that will travel to its site of action as rapidly as possible. Peptides have shown promising pharmacokinetic profiles of being freely diffusible with rapid transit to the target site. Antibodies have shown effective targeting capabilities and improved biodistribution with pretreatments. As new constructs with better targeting capabilities are being explored, the maximization of therapeutic potential becomes imaginable. As a non-targeted α-emitter,
223
Ra is now a FDA approved therapeutic option in metastatic prostate cancer, and has recently opened a new avenue for α-therapy.
212
Pb could represent a new addition to the field of nuclear medicine, based on several advantages, such as its ability to be conjugated, optimal decay in two α-emitters ( 211 Bi and 212 Po), short half-life, method of production, γ-emission for specific imaging companion studies, development of optimized chelators (such as TCMC) that increase 212 Pb stability. The toxicities of TAT can be minimized with improvements in targeting moieties and chelators, as well as a better understanding of diseases. Limiting toxicities to the liver and kidney should be clearly addressed both in the preclinical toxicology studies and the design of the phase I clinical trials.
The therapeutic application of these isotopes has been a hot topic of interest for the last 15 years. If production can meet demands, the applications can be expanded to more targeting agents in a broader spectrum of tumor types. The early phase of development of targeted α-therapies requests specific collaborative efforts between expert teams and investigators that include in particular medical oncologists, radiopharmacists, physicists, and nuclear medicine physicians in established centers of excellence. By contrast, in its later stage of development or after FDA-approval, the recent technological developments should facilitate the utilization and the dissemination of TAT in a vast number of centers including academic and large community practices.
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